Wilms' tumor gene 1 (WT1) functions including some contradictory effects may be explained by the presence and interactions of its isoforms, however, their evaluation has been so far complicated by several technical problems. We designed unique quantitative PCR systems for direct quantification of the major
INTRODUCTION
Wilms' tumor gene 1 (WT1) has been intensively studied because of its important role in embryogenesis and oncogenesis, as a potential new prognostic factor, minimal residual disease marker and target of vaccination immunotherapy in various malignancies, particularly in acute myeloid leukemia (AML; reviewed [1] [2] [3] [4] [5] [6] [7] . Although there is an increasing number of genes and signaling pathways WT1 has been shown to interact with, the actual relevance and input of WT1 to the malignant process has yet to be elucidated. It seems probable that at least several aspects influence and contribute to the final outcome of the WT1 pro-or antioncogenic effect: deregulation of WT1 expression, discrepancy in the proportion of functionally differing WT1 isoforms, interactions with other factors and cofactors and the particular status and perceptiveness of the cell. Disturbed WT1 regulatory function may alter the mesenchymal-epithelial balance, resulting in malignant proliferation as well as non-malignant diseases associated with the WT1 gene (for example, glomerulosclerosis). 8, 9 WT1 is located on chromosome 11p13 and encodes a zincfinger transcription factor. It activates or more often represses the transcription of many target genes involved in the cell cycle, proliferation, differentiation and apoptosis control, and is also involved in post-transcriptional mRNA processing. 3, [10] [11] [12] At least 36 isoforms of WT1 protein are produced from the same DNA template as a result of alternative transcription initiation, alternative pre-mRNA splicing, mRNA editing and alternative translation initiation. 1, 3, 5, 10, [13] [14] [15] [16] [17] [18] The four major WT1 isoforms are generated by an alternative splicing and vary in the presence or absence of so called 17AA insert (17 amino acids encoded by the whole exon 5) and KTS insert (according to the three amino acids leucinethreonine-serine encoded by the terminal sequence of exon 9)- [19] [20] [21] [22] [23] An alternative WT1 transcript, AWT1 (also short transcript, sWT1), maintains WT1 exonic structure between exons 2 and 10 but uses another first exon located in intron 1 of WT1 (exon 1a). It may otherwise exist in all splicing variants characteristic of WT1. 14, 15 Another N-terminally truncated transcript, lacking exons 1-5, has been previously described and the presence of a cryptic promoter within WT1 intron 5 hypothesized. 24, 25 All of these modifications markedly influence the activity of WT1 protein.
The KTS insert is located between the protein's third and fourth zinc finger and alters the spacing between these fingers, changing the DNA recognition site and decreasing the DNA-binding ability. The 17AA (EX5) insert is located in the middle of the protein and may function as a transcriptional activation domain. The AWT1 transcript does not contain the repression domain ( Figure 1 ). 1,3,14,15,26,27 1 Isoforms containing both splice inserts are the prevalent variants, the least common transcripts are those missing both inserts, and the physiological ratio of A[
seems to be stable during the development of WT1 expressing tissues; for fetal kidney and Wilms' tumors, the ratio referred is 1.0 : 2.5 : 3.8 : 8.3. 10 An altered ratio of WT1 KTS[ þ ]/ KTS[ À ] variants caused by defective splicing has been described in rare pre-malignant syndromes (Frasier syndrome, Denys-Drash syndrome). [28] [29] [30] [31] In AML, significantly higher expression levels of EX5[ þ ] variants at diagnosis and at relapse have been detected. 26, 32, 33 In addition, the alternative AWT1 transcript has been found to be overexpressed in leukemia samples. 15, 34 Functional studies suggest that many of WT1 effects are related to particular WT1 isoforms. 8, 20, [35] [36] [37] [38] [39] [40] The available data on WT1 isoform expression patterns in normal and malignant hematopoiesis are scarce and the methods so far used for the detection of WT1 major isoforms (reverse transcriptase PCR, GeneScan, quantitative PCR of EX5[ þ ] and KTS[ þ ] variants) have only yielded an approximate estimation of WT1 isoform levels.
The main aim of this project was to design and optimize a realtime quantitative PCR (qPCR) method that would enable precise quantification of the four major WT1 variants, and using this method to determine the ratio of WT1 isoforms in healthy donors, leukemic cell lines, childhood and adult AML and in myelodysplastic syndrome (MDS) samples, to demonstrate their clinical relevance. Table S1 ) were cultured according to the supplier's recommendations. They were used for method optimization, validation studies and as positive controls.
MATERIALS AND METHODS

Samples Cell lines. Eight leukemic cell lines (Supplementary
For tests of WT1 expression stability, cell lines were harvested (in triplicate) 24, 48 and 72 h after the start of culture and further processed.
Patients samples. Following ethical committee approval and informed consent, 73 diagnostic BM samples from childhood patients with AML treated from 1994 to 2009 in the Czech Pediatric Hematology Working Group centers and at the University Hospital in Jena, Germany, were collected on a consecutive basis. For comparison, further diagnostic BM samples from related diseases were tested, including 20 samples of childhood MDS, 9 samples of childhood SAA, both diagnosed and treated from 1994 to 2011 in the same hospitals, 30 samples from adult AML and 29 from adult MDS, managed from 1998 to 2011 in the Institute of Hematology and Blood Transfusion, Prague, Czech Republic (Table 1) .
In addition, 23 non-malignant BM samples were used as negative controls. These were obtained from healthy donors or from leukemia patients in long-term complete remission with confirmed MRD negativity.
Methods
Sample processing. BM samples were collected into sterile tubes with anticoagulant, immediately transported to the lab and processed. Mononuclear cells were separated on a density gradient medium (Ficoll-Paque Plus, GE Healthcare Life Sciences, Uppsala, Sweden) and stored at À 80 1C. RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany),
WT1p
KTSp Figure 1 . Scheme of WT1 gene and protein and qPCR detection systems. WT1 gene and its products (a)-alternative splice sites are crosshatched, black arrows indicate alternative transcription initiation sites. qPCR detection systems for total WT1 and its main isoforms (b)-primers indicated by gray arrows, probes by black rectangles, their detailed description is given in Table 2 .
its concentration was evaluated by spectrophotometry (Nanodrop, Thermo Fisher Scientific, Waltham, MA, USA). The cDNA synthesis was performed using the iScript kit (Bio-Rad, Hercules, CA, USA) starting from 1 mg of total RNA. qPCR for total WT1. Quantification of total WT1 expression was performed by qPCR of our own design, 41 which performance is quite comparable with a commercially available WT1 kit (WT1 ProfileQuant, Ipsogen, Marseille, France).
Capillary electrophoresis and fragment analysis (GeneScan) detection of WT1 isoforms. As a reference method, detection of WT1 isoforms was performed by capillary electrophoresis and fragment analysis as described previously. 42 RT-PCR for WT1 isoforms. RT-PCR assays for separate detection of the four main WT1 isoforms were established with several sets of primers located on exon 5 (EX5 þ ), the exon 4/exon 6 boundary (EX5 À ), KTS (KTS þ ) and the exon 9/exon 10 boundary (KTS À ). PCR products were analyzed by electrophoresis on agarose gel or by capillary electrophoresis (Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA), as described elsewhere.
Plasmid calibrators for WT1 isoforms. Products of RT-PCR with primers located on exon 4 and exon 10 of WT1 gene were cloned using the TOPO TA Cloning kit (Invitrogen, Life Technologies, Carlsbad, CA, USA) as described previously. 41 The WT1 isoforms were identified by RT-PCR and selected clones were used for bulk plasmid production. Figure 1 and Table 2 . The qPCR reaction was performed on the Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) or LightCycler 480 (Roche Diagnostics, Basel, Switzerland). ABL was used as a control gene; detection of WT1 was carried out in triplicate, detection of ABL and calibrators in duplicate. Samples were considered positive if at least one reaction of the replicate was positive, and negative if all reactions were negative, within the detection range. WT1 (total and isoform) and ABL copy number and WT1 normalized copy number (NCN ¼ WT1/ABL Â 10 4 ) were calculated from the plasmid standard curves. The ratio of WT1 isoforms was counted as their proportion of all WT1 isoforms sum. From the variants Statistical analysis. Results were analyzed using statistical software (Excel, Microsoft, Redmond, WA, USA; Prism, GraphPad, La Jolla, CA, USA; R-project, Vienna, Austria). Correlations of results in between the different assays were checked by non-parametric Spearman's rank correlation. Group comparisons were performed by non-parametric Kruskal-Wallis test with Dunn's multiple comparison post test. Possible dependence of WT1 isoform expression patterns on total WT1 values was tested using linear regression modeling. The prognostic potential of WT1 isoform expression was evaluated by logistic regression. Multinominal logistic regression was used to assess the relation of total WT1 and WT1 isoform expression to specific diagnoses and their ability to separate the particular diagnoses RESULTS qPCR for WT1 isoforms-assay performance Sensitivity. The main characteristics of standard curves generated by plasmid calibrators and cell line 10-fold dilution series were quite comparable with those of qPCR for total WT1 and ABL control gene (slope 3.19 to À 3.40, intercept 38.45-38.87, mean C t of 10 5 copies 21.80-23.00 for plasmid calibrators). The reliable sensitivity threshold for each isoform was identified as 10 1 plasmid copies, which was the lowest plasmid concentration used; it always generated positive results, in each reaction in replicates and for each of the four detected isoforms. Addition of the other three isoforms in much higher concentrations (10 5 copies of each) did not affect this sensitivity (Supplementary Figure S1) . The sensitivity of various cell line dilution series reached 10 À 2 to 10 À 4 , depending on their total WT1 expression level.
Specificity. In extensive testing, no unspecific, cross-reaction positivity was detected within the detection range (cycles 11 À 40). The reactions for any of the three isoforms other than the specific one, even in high plasmid concentrations of 10 5 copies, were always negative (very weak positivities were noticed with nonspecific plasmids in high concentrations of 10 5 copies coming up after cycle 41, at least 6 cycles after the positivity of the specific plasmid in the lowest concentration 10 1 copies. Supplementary Figure S1 ).
Reproducibility. Variations in detected levels and ratios of WT1 isoforms within the same samples were minimal, as confirmed by multiple processing and testing of the samples-in replicates (six replicates) and in repeated experiments. These validation experiments were performed by two independent investigators, using two different qPCR systems (AB 7500, Roche LC480). There was an excellent correlation between the sum of WT1 isoforms and the measured total WT1 expression (Spearman's rank correlation, Rho ¼ 0.972, Po0.0001); in absolute values, the sum of WT1 isoforms was 0.5-1.0 log lower than the amount of total WT1. In cell line dilution experiments, WT1 isoform ratios remained constant in samples with total WT1 expressionX100 copies and/or the sum of WT1 isoform expressionX10 copies. In cases of lower-that means very low-WT1 expression, the determined WT1 isoform ratio may not be correct and its interpretation therefore impossible. Detection of WT1 isoforms by qPCR demonstrated higher sensitivity and accuracy than RT-PCR and GeneScan assays. Despite the significant differences in total WT1 expression levels of morphologically and cytogenetically defined subgroups, the ratio of WT1 isoforms was constant across these subgroups (Figure 4) . Children with the FLT3/ITD mutation had the same WT1 isoform profile as those with the wild-type FLT3 gene; the same applied to patients of different risk groups. Relapsed patients had an identical WT1 isoform pattern to patients who remained in complete remission, and no relation between the isoform ratio and the risk of relapse could be observed in logistic regression analysis.
WT1 isoform expression patterns in childhood MDS and SAA. A total of 20 patients with childhood MDS expressed total WT1 at significantly lower levels compared with AML (median 196, range 0-4221 WT1/ABL Â 10 4 NCN; P ¼ 0.003); in RAEB subtype, the total WT1 expression was higher (638, 325-2645 NCN) and less fluctuating than in RC subtype (22, 0-4221 NCN; Figures 3 and 4) . The analysis of WT1 isoforms could be performed in 12 patients with sufficient total WT1 levels. In comparison with AML, different and more variable ratios of WT1 isoforms were found in children with MDS, with an abundance of variant D and similar levels of isoforms A, B and C-the median ratio of A, B, C and D was 0.16 : 0.15 : 0.17 : 0.46, D4CEBEA.
SAA was associated with very low total WT1 expression, similar to or even lower than physiological WT1 expression in control BM samples (median 4, range 2-26 WT1/ABL Â 10 4 NCN; Figure 3 ). Therefore, analyses of WT1 isoforms in SAA patients could not be performed.
WT1 isoform expression patterns in adult AML and MDS. The median total WT1 expression in 30 adults with AML was 3446 WT1/ABL Â 10 4 NCN (range 2-23579), which was comparable to the level detected in childhood AML (Figure 3) . In 27 patients, analyzed for the expression pattern of WT1 isoforms, the median ratio of the isoforms A, B, C and D was 0.13 : 0.31 : 0.13 : 0.45, respectively, D4B4CEA. Variations among adult patients were smaller compared with the childhood data. Although there were differences in the levels of respective variants between adults and children, the general expression profile of WT1 isoforms was uniform in both types of AML. Likewise, the ratio of WT1 WT1 isoforms in acute myeloid leukemia K Kramarzova et al 
Reaction conditions
Component qPCR for total WT1 qPCR for WT1 isoforms cDNA 5 ml (10% of RT mixture) 5 ml (10% of RT mixture) Fwd primer (15 mM) 0.5 ml (300 nM) 1 ml (600 nM) Rvs primer (15 mM) 0.5 ml (300 nM) 1 ml (600 nM) Probe (5 mM) 1 ml (200 nM) 1 ml (200 nM) dNTPs (10 mM) 2 ml (800 mM) MgCl 2 (25 mM) 2 ml (2 mM) PCR buffer 10X 2.5 ml Taq DNA polymerase (5 U/ml) a 0.2 ml ROX-5 or ROX-6 (10 mM) Figure 3 ). Likewise the aforementioned childhood samples, the seven adult MDS samples analyzed showed variable expression of WT1 isoforms with median ratios 0.12 : 0.22 : 0.21 : 0.41 for isoforms A, B, C and D, respectively, D4CEB4A.
Relation of WT1 isoform expression patterns to diagnosis. Unsupervised hierarchical cluster analysis according to the expression pattern of WT1 isoforms indicated that the clinical samples could be separated into discrete clusters representing the different diagnoses. Multinominal logistic regression and w 2 tests on residual deviance confirmed the significance of diagnosis determination by WT1 isoform expression ratios and their superiority over total WT1 (Po0.0001; Figure 5 ). In linear regression, WT1 isoform expression patterns proved to be independent of total WT1 expression. . n refers to number of patients analyzed for total WT1 expression/ WT1 isoform expression. P refers to results of Kruskal-Wallis tests with Dunn's multiple comparison post tests.
than would be expected if exon 5 and KTS insert were spliced quite randomly and independently.
DISCUSSION
The exact quantification of the major WT1 isoforms, essential for assessment of their activities in regulatory processes and cellular signaling, has been complicated by technical difficulties caused by the length and sequence homology of the isoforms. We managed to overcome these difficulties and, after testing several approaches, developed a unique qPCR assay enabling precise quantification of the four major WT1 isoforms. The robustness of this method, its sensitivity, specificity and reproducibility were verified in extensive tests, and it may be recommended for any further studies on WT1 isoform expression. During the method validation, a few important aspects of WT1 isoform quantification emerged. Despite the excellent correlation between the sum of isoforms and the total WT1, the absolute numbers of detected copies of all isoforms are always lower than total WT1 expression (0.5-1.0 log in this study). Although it is possible that total WT1 values include some other WT1 isoforms than the four major detected (for example, isoforms lacking the first five exons), the main reason of this discrepancy will probably be the unequal performance of the qPCR detection systems for total WT1 and the isoforms, which must be generally lower in cases of WT1 isoforms with very long amplicons. Although it means that the sensitivity of isoform detection is slightly lower compared with total WT1, it is crucial that the enumeration of their ratios is not affected, as follows from dilution experiments. Owing to the potential unequal performance of reactions for WT1 isoforms and total WT1, we strongly recommend to perform always detection of both EX5 
respectively, which has been described previously and could give misleading results. Dilution experiments also revealed that a certain minimal level of WT1 expression is necessary for a reliable evaluation of isoform ratio; in samples with very low total WT1 expression and only few single copies of isoforms being detected, evaluation of WT1 isoform ratio is impossible or will be inaccurate. This logical assay limitation should be considered especially when comparing WT1 isoform ratios in leukemic cells expressing higher levels of total WT1 and normal BM with quite low total WT1 expression-otherwise the differences found may not reflect the real imbalances in WT1 ratios but rather reaching the method limits in the control samples. With respect to this fact, we would interpret the previously referred differences between physiological and leukemic ratios of WT1 isoforms with caution. In leukemic cell lines, highly diverse expression patterns of WT1 isoforms were detected and no specific profile could be assigned to cell lines with certain common characteristics (leukemia type-lymphoid vs myeloid, cytogenetic aberrations-TEL-AML1, MLL-AF4). The two most related cell lines (REH and UOC-B6, both pre-B-ALL with TEL-AML1 fusion) showed the most different WT1 isoform expression patterns; on the contrary, the two cell lines with the most similar expression patterns, which were distinct from the rest (NALM-6 and REH), do not share any apparent common features other than pre-B origin. A plausible explanation might be that the isoform expression pattern depends on the growth phase and proliferation rate of the cells in culture rather than on the cell line characteristics. We therefore evaluated WT1 isoform expression in three cell lines at several time-points from the beginning of culture and showed that despite slight fluctuation of total WT1 expression, which has been described previously and related to the cell cycle phase, 46 the levels of respective variants remained markedly stable. Thus, WT1 isoform expression patterns appear to be rather determined by the intrinsic characteristics of the leukemic cells.
There were significant differences in total WT1 expression in clinical samples with particular diagnoses. In AML and MDS, there were also different total WT1 levels among distinct FAB subtypes and subgroups with specific molecular aberrations. These findings have been previously described and are in concordance with results of other studies. [47] [48] [49] [50] [51] [52] [53] [54] [55] WT1 isoform expression patterns showed at first glance subtle but significant differences among normal BM, AML and MDS, and also between childhood and adult samples. These specific patterns enabled the clustering of samples into groups representing the individual diagnoses. Although more profound alterations of isoform profile could have been expected when comparing normal, dysplastic and malignant BMs, it is not surprising that in the complex and very precise regulatory mechanisms of WT1 even slight imbalance in isoform ratios may have considerable effect and serious outcomes for the concerned cells. The isoform expression patterns were more uniform in AML than in MDS, 
